[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xinjiang Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":260},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,53,76,100,132,153,177,196,218,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100640884","structured-cardio-oncology-rehabilitation-for-cardiovascular-outcomes-in-cancer-survivors-100640884",false,"NCT07622394","Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors","A Multicenter, Prospective, Parallel-Group, Superiority Randomized Controlled Trial of Structured Cardio-Oncology Rehabilitation for Improving Cardiovascular Outcomes in Patients With Cancer Therapy-Related Cardiac Dysfunction or High Cardiovascular Risk","CORE-CTRCD","Inclusion Criteria:\n\n* Age 18 years or older, regardless of sex.\n* Histologically or cytologically confirmed solid tumor or hematologic malignancy.\n* Completed curative anti-cancer therapy, or receiving stable adjuvant, maintenance, or palliative anti-cancer therapy.\n* Meets at least one criterion for cancer therapy-related cardiac dysfunction (CTRCD) or high cardiovascular risk, including reduced LVEF after anti-cancer therapy, high-dose anthracycline exposure, chest radiotherapy with cardiovascular risk factors, heart failure after anti-cancer therapy, or elevated cardiac injury\u002Fheart failure biomarkers.\n* Estimated life expectancy of at least 24 months as assessed by the treating oncologist.\n* Able to complete baseline cardiopulmonary exercise testing and has no absolute contraindication to exercise training.\n* Able and willing to provide written informed consent and comply with study intervention and follow-up.\n\nExclusion Criteria:\n\n* Active progressive malignancy requiring urgent anti-cancer therapy, or estimated life expectancy less than 24 months.\n* Severe structural heart disease, including severe valvular disease, congenital heart disease, end-stage heart failure, or waiting for heart transplantation or left ventricular assist device implantation.\n* Absolute contraindications to exercise training, including uncontrolled malignant arrhythmia, acute myocarditis or pericarditis, acute coronary syndrome within 2 weeks, severe anemia, severe thrombocytopenia or neutropenia, uncontrolled hypertension, active infection, or severe musculoskeletal disease preventing exercise training.\n* Participation in a structured cardiac rehabilitation program within the previous 12 months, or regular moderate-to-vigorous aerobic or resistance training for at least 3 months before enrollment.\n* Implanted ICD or CRT, except pacemakers with exercise mode.\n* Severe psychiatric disease or cognitive impairment preventing participation.\n* Concurrent participation in another interventional clinical trial, or planned participation in another interventional clinical trial during the study period.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","ALL","18 Months",{"count":20,"type":21},800,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management, high-quality randomized controlled evidence regarding its efficacy in cardio-oncology populations remains limited.\n\nThis multicenter, prospective, parallel-group, superiority randomized controlled trial aims to evaluate whether a structured cardio-oncology rehabilitation (CORE) program combined with usual care can improve cardiovascular outcomes in patients with CTRCD or cancer survivors at high cardiovascular risk, compared with usual care alone.\n\nA total of 800 participants will be randomized in a 1:1 ratio to receive either structured cardio-oncology rehabilitation plus usual care or usual care alone. The intervention includes individualized exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education. Participants will be followed for 12 months.\n\nThe primary endpoint is time to first major adverse cardiovascular event (MACE) within 12 months. Secondary endpoints include changes in cardiorespiratory fitness, cardiac function, biomarkers, quality of life, physical function, psychological status, safety outcomes, and health economic outcomes.",[27,28,29,30,31],"Cancer Therapy-Related Cardiac Dysfunction","Cardio-oncology","Cancer Survivorship","Cardiovascular Risk","Heart Failure",[33,34,35,36,37,38,39],"Structured Cardio-Oncology Rehabilitation","Cardiac Rehabilitation","Cancer Survivors","Major Adverse Cardiovascular Events","Exercise Training","Cardiorespiratory Fitness","CTRCD","NOT_YET_RECRUITING","2026-06-02",{"date":43,"type":44},"2026-06-03","ACTUAL",{"date":46,"type":21},"2026-09-01",{"date":48,"type":21},"2029-09-30",{"name":50,"class":51},"Xinjiang Medical University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100634032","the-prognostic-value-of-cardiopulmonary-exercise-testing-parameters-in-patients-with-coronary-heart-disease-a-retrospective-cohort-studycpetpcad-100634032","NCT07534410","The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study(CPETPCAD)","The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study","CPET-PCHD","Inclusion Criteria:\n\n1. Our hospital has diagnosed coronary heart disease and conducted cardiopulmonary exercise tests.\n2. Patients with complete clinical data.\n\nExclusion Criteria:\n\n1. Uncontrolled heart failure (NYHA classification Ⅲ-IV grade).\n2. Complications, such as moderate to severe anemia, tumors and lung diseases.\n3. Complicated with valvular heart disease.\n4. Unable to reach the anaerobic threshold during exercise.","18 Years",{"count":63,"type":21},15000,"OBSERVATIONAL","Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. This is a retrospective cohort study designed to systematically collect real-world clinical data and long-term follow-up outcomes of patients with coronary heart disease. Through standardized follow-up, this study will investigate the association between CPET parameters and adverse clinical outcomes in patients with coronary heart disease, as well as the relevant risk factors.",[67],"Coronary Heart Disease (CHD)","2026-04-09",{"date":70,"type":44},"2026-04-16",{"date":72,"type":21},"2026-04-07",{"date":74,"type":21},"2027-06-30",{"name":50,"class":51},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":64,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100622019","prognosis-of-primary-aldosteronism-a-prospective-cohort-study-100622019","NCT07378176","Prognosis of Primary Aldosteronism: A Prospective Cohort Study","PA-PROG","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).\n3. Voluntary to sign the informed consent.\n\nExclusion Criteria:\n\n1. patients with severe cardiac, hepatic or renal dysfunction;\n2. Diagnosis of secondary hypertension other than PA.","80 Years",{"count":85,"type":21},5000,"60 Months","Primary aldosteronism (PA) is the most common cause of secondary hypertension, and patients with PA have a significantly higher risk of developing cardiovascular and renal complications compared with those with essential hypertension. However, PA remains substantially underdiagnosed and undertreated in clinical practice, and relevant research data on the short-term and long-term prognosis of PA patients in the Chinese population are particularly scarce. This is a multicenter, prospective cohort study designed to systematically collect real-world clinical data of PA patients, including baseline clinical characteristics, etiological subtypes, diagnostic and therapeutic strategies, and long-term follow-up outcomes. Through 5 years of standardized follow-up, this study will analyze the differences in treatment efficacy among PA patients with different pathological subtypes (e.g., adrenal adenoma, adrenal hyperplasia), evaluate the short-term therapeutic efficacy and long-term prognosis of PA patients undergoing different treatment modalities including pharmacotherapy, surgery and interventional therapy, and explore the risk factors for adverse clinical outcomes. Ultimately, it will provide high-quality real-world evidence-based data to optimize the clinical diagnosis and management of PA and improve the long-term prognosis of affected patients.",[89],"Primary Aldosteronism","RECRUITING","2026-02-02",{"date":93,"type":44},"2026-02-03",{"date":95,"type":44},"2026-01-30",{"date":97,"type":21},"2031-12",{"name":50,"class":51},2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":17,"minAge":61,"maxAge":83,"enrollmentInfo":108,"targetDuration":110,"studyType":64,"phases":4,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":52},"100620243","precision-subtyping-and-prognostic-study-of-heart-failure-based-on-multi-omics-integration-and-clinical-indicators-a-prospective-single-center-cohort-study-100620243","NCT07355088","Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study","HF-MultiOmics","Inclusion Criteria:(1)For chronic heart failure (CHF) patients:1.Meet the 2022 European Society of Cardiology (ESC) diagnostic criteria for CHF, classified into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) per ESC guidelines;2.Aged 18 to 80 years (inclusive);3.Able to provide written informed consent independently (or via a legal guardian if cognitively impaired, with a Mini-Mental State Examination \\[MMSE\\] score ≥ 24).\n\n(2)For healthy controls:1.No history of cardiovascular disease, confirmed by medical history review and baseline echocardiography;2.Aged 18 to 80 years (inclusive), matched 1:2 with CHF patients by age and gender;3.Able to provide written informed consent.\n\nExclusion Criteria:(1)Acute decompensated heart failure (admitted for acute HF exacerbation within 72 hours prior to enrollment);(2)End-stage renal disease, defined as an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m² (confirmed by serum creatinine testing);(3)Active malignancies (receiving systemic treatment within 6 months prior to enrollment) or severe systemic diseases (e.g., severe liver failure, active autoimmune diseases);(4)Antibiotic use within 2 weeks prior to enrollment (may interfere with gut microbiome analysis);(5)Inability to complete 12-month follow-up (e.g., planned long-term overseas residence) or provide required biological samples (e.g., venous blood, fecal samples).",true,{"count":109,"type":21},600,"12 Months","This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy controls.We will collect clinical data (e.g., NYHA class, NT-proBNP), multi-omics samples (genome, proteome, metabolome, gut microbiome), and imaging indicators (e.g., EAT density, myocardial strain) from participants at baseline. For patients treated with SGLT2 inhibitors, we will also track dynamic changes in multi-omics during follow-up.The main purpose is to build a composite risk prediction model (integrating multi-omics and clinical indicators) to predict the 1-year composite endpoint (heart failure rehospitalization or all-cause death). Secondary goals include identifying specific molecular profiles related to heart failure phenotypes, exploring the \"gut-heart axis\" mechanism, and finding early biomarkers for SGLT2 inhibitor response.All participants will be followed up for at least 12 months, and the study will strictly comply with ethical norms and protect the privacy of participants.",[113,114,115,116],"Chronic Heart Failure","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Preserved Ejection Fraction (HFPEF)","Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)",[113,118,119,120,121,122,123],"Multi-omics","Gut-heart axis","SGLT2 inhibitors","Risk prediction model","Epicardial Adipose Tissue","Myocardial Strain","2026-01-12",{"date":126,"type":44},"2026-01-21",{"date":128,"type":21},"2026-01-01",{"date":130,"type":21},"2028-03-01",{"name":50,"class":51},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":86,"studyType":64,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":152,"locationsCount":99},"100616366","the-association-between-primary-aldosteronism-and-cognitive-dysfunction-100616366","NCT07304674","The Association Between Primary Aldosteronism and Cognitive Dysfunction","PACD","Inclusion Criteria:\n\n* 1\\. Aged ≥ 40 years.\n* 2\\. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).\n* 3\\. Ability to understand and cooperate with comprehensive neuropsychological assessment.\n* 4\\. Voluntary participation and provision of written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Significant visual, hearing, or motor impairment that prevents completion of cognitive testing.\n* 2\\. History of major neurological disorders (e.g., stroke, Parkinson's disease, intracranial tumor, severe traumatic brain injury).\n* 3\\. History of major psychiatric illness, intellectual disability, or current use of antipsychotic medications.\n* 4\\. Diagnosis of secondary hypertension other than PA.\n* 5\\. Unwillingness to participate by the patient or their legal representative.","40 Years",{"count":141,"type":21},1000,"The goal of this observational study is to learn about the prevalence, progression, and influencing factors of cognitive impairment in patients with primary aldosteronism (PA). The main questions it aims to answer are:\n\n1. What is the prevalence of baseline cognitive impairment in PA patients and what factors are associated with it?\n2. What is the incidence of cognitive progression in PA patients within 1 and 5 years of follow-up and what factors influence this progression? Participants who are already diagnosed with PA as part of their regular medical care will be invited to join this long-term study. They will complete regular cognitive tests, medical check-ups, and questionnaires for up to 5 years. Some participants will also have optional blood tests and brain scans to help researchers understand the causes behind any cognitive changes.",[89,144,145,146],"Cognitive Dysfunction","Mild Cognitive Impairment (MCI)","Dementia",{"date":148,"type":44},"2026-01-05",{"date":150,"type":44},"2025-12-31",{"date":97,"type":21},{"name":50,"class":51},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":52},"100555553","primary-aldosteronism-superselective-embolization-vs-laparoscopic-endocrine-curative-therapy-100555553","NCT06513585","Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy","The First Affiliated Hospital of Xinjiang Medical University","PA-SELECT","Inclusion Criteria:\n\n* Age 18-60\n* Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society\n* Primary aldosteronism diagnosed according to international guidelines Unilateral disease by AVS or PET-CT criteria\n* Patients and their family members signed informed consent and agreed to participate in the study\n\nExclusion Criteria:\n\n* A history of severe hypersensitivity to contrast media\n* Severe liver disease complications, such as thrombocytopenia, esophageal varices rupture bleeding, etc\n* Renal insufficiency (serum creatinine \\> 176mmol\u002FL or estimated glomerular filtration rate \\\u003C min.1.73m2)\n* Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogen, herbal medicines containing glycyrrhizin), pregnancy hypertension and other secondary hypertension\n* Combined with genetic diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesia (Gitelman syndrome)\n* Stroke, myocardial infarction and stent implantation occurred in the past 3 months\n* Serious other diseases, such as heart dysfunction (grade IV), acute infections, autoimmune diseases, various malignant tumors, etc\n* Participated in other clinical trials within the past 3 months\n* Pregnant, breastfeeding, or planning a pregnancy\n* Identify patients with alcohol allergy","60 Years",{"count":163,"type":21},570,[24],"The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.",[89,167,168],"Suprarenalectomy","Super Selective Adrenal Artery Embolization","2025-04-14",{"date":171,"type":44},"2025-04-15",{"date":173,"type":44},"2024-08-01",{"date":175,"type":21},"2026-12-01",{"name":50,"class":51},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":158,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":161,"enrollmentInfo":183,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":52},"100555560","super-selective-adrenal-artery-embolization-for-primary-aldosteronism-a-prospective-cohort-studysaae-pa-100555560","NCT06513676","Super Selective Adrenal Artery Embolization for Primary Aldosteronism: a Prospective Cohort Study(SAAE-PA)","Inclusion Criteria:\n\n* Age 18-60 years old;\n* Primary hyperaldosteronism was diagnosed in strict accordance with the 2016 International Endocrine Society clinical guidelines;\n* Refusal of medication due to adverse reactions, refusal of adrenal resection due to surgical risk, or persistent hyperaldosteronism and cortical insufficiency after adrenal resection;\n* The patients and their families were introduced in detail to all the current treatment methods for primary aldosteronism, and the adrenal artery embolization was voluntarily accepted;\n\nExclusion Criteria:\n\n* A history of severe hypersensitivity to contrast media;\n* There are serious complications of liver disease, such as thrombocytopenia, esophageal variceal bleeding, etc;\n* Renal insufficiency (serum creatinine \\> 176mmol\u002FL or estimated glomerular filtration rate \\\u003C min.1.73m2);\n* Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogens, herbs containing glycyrrhizin), pregnancy hypertension and other secondary hypertension;\n* Hereditary diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesemia (Gitelman syndrome);\n* Cerebral apoplexy, myocardial infarction and stent implantation occurred in the past 3 months;\n* Serious other basic, such as heart dysfunction (grade IV), acute infection, autoimmune diseases, various malignant tumors and so on;\n* Participated in other clinical trials within the past 3 months;\n* Individual pregnancy, nursing or planning pregnancy;",{"count":184,"type":21},500,"The objective of this study was to evaluate the efficacy and safety of adrenal vein blood extraction for primary aldosteronism classification and adrenal artery embolization in the treatment of primary aldosteronism, to provide new evidence plan for the diagnosis and treatment of primary aldosteronism, and to promote the development of adrenal artery embolization as a new treatment for primary aldosteronism.",[89,187],"Super Selective Adrenal Arterial Embolization","2024-07-22",{"date":190,"type":44},"2024-07-23",{"date":192,"type":44},"2024-04-15",{"date":194,"type":21},"2028-08-01",{"name":50,"class":51},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":83,"enrollmentInfo":204,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":52},"100551426","clinical-outcomes-of-cardiovascular-disease-100551426","NCT06459934","Clinical Outcomes of Cardiovascular Disease","Clinical Outcomes of Cardiovascular Disease: a Prospective Cohort Study","CLEAR","Inclusion Criteria:\n\n1. Coronary heart disease According to coronary angiography and coronary CTA, at least one coronary artery has a degree of stenosis greater than 50%.\n2. Hypertension Hypertension is defined as office systolic blood pressure is ≥ 140mmHg and\u002For the diastolic blood pressure is ≥ 90mmHg without the use of antihypertensive drugs.\n3. Heart failure There is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure.\n4. Cardiomyopathy Including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.\n5. Able to sign informed consent form.\n\nExclusion Criteria:\n\n1. Age\\\u003C18 years old, or\\>80 years old.\n2. Patients with various malignant tumors.\n3. Liver dysfunction (defined as ALT or total bilirubin greater than three times the upper normal limit).\n4. Renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit).\n5. Those who have participated in other clinical studies within the past three months.\n6. Individuals without legal capacity or with limited legal capacity.\n7. Any situation where the researcher deems it unsuitable to participate in the clinical study.",{"count":205,"type":21},30000,"This study is a prospective, single center cohort study that primarily registers the clinical characteristics, outcomes, and influencing factors of patients with different types of cardiovascular diseases. Evaluate multiple examination indicators of patients at baseline, 1 year and longer, and follow up on the incidence of major cardiovascular and cerebrovascular adverse events, heart failure readmission, death, and other endpoint events.",[208,31,209],"Cardiovascular Diseases","Coronary Artery Disease","2024-06-14",{"date":212,"type":44},"2024-06-18",{"date":214,"type":44},"2024-06-01",{"date":216,"type":21},"2028-12-31",{"name":50,"class":51},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":52},"100528449","prognostic-model-of-hypertension-100528449","NCT06160921","Prognostic Model of Hypertension","PHOP-HT","Inclusion Criteria:\n\n* A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University\n\nExclusion Criteria:\n\n* Patients with secondary hypertension, patients with liver and kidney dysfunction,\n* patients with mental disorders, and patients who are unwilling to participate in this trial",{"count":226,"type":21},50000,"The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.",[229],"Hypertension","2024-03-26",{"date":232,"type":44},"2024-03-28",{"date":234,"type":44},"2020-01-01",{"date":236,"type":21},"2030-01-01",{"name":50,"class":51},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":158,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":245,"maxAge":83,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":52},"100494247","renal-denervation-in-patients-with-chronic-heart-failure-with-preserved-ejection-fraction-100494247","NCT05715697","Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction","RDN-HFPEF","Inclusion Criteria:\n\n1. signs or symptoms of heart failure;\n2. normal or mildly abnormal systolic LV function (LVEF ≥ 50%);\n3. evidence of diastolic LV dysfunction.\n4. Individual should fulfill the diagnostic WHO criteria for hypertension: SBP \\> 140 mmHg and\u002For DBP \\> 90 mmHg, and is treated with at least 2 antihypertensive drugs. This treatment is expected to be maintained for at least 6 months. Using this regimen the blood pressure should be adequately controlled (\\\u003C 140\u002F90mmHg by 24 hour ambulatory BP measurement).\n5. Individual is adhering to a stable drug regimen HFNEF, with no changes for a minimum of 2 weeks prior to enrollment, and which is expected to be maintained for at least 6 months.\n\nExclusion Criteria:\n\n1. Known secondary cause of hypertension\n2. Anatomy not eligible for renal denervation\n3. Systolic heart failure (LVEF \\\u003C 50%)\n4. Individual has an estimated glomerular filtration rate (eGFR) of \\\u003C 30mL\u002Fmin\u002F1.73m2, using the MDRD calculation.\n5. Individual has any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and\u002For effectiveness of the participant or the study (i.e., patients with clinically significant peripheral vascular disease, abdominal aortic aneurysm, bleeding disorders such as thrombocytopenia, haemophilia, significant anaemia, or arrhythmias such as atrial fibrillation).\n6. Individual is pregnant, nursing or planning to be pregnant.","21 Years",{"count":247,"type":21},200,[24],"This study aims to explore the potential of RDN as a therapy for HFpEF in a Prospective, Multicenter, Randomized, Blinded, Sham-controlled Study.",[251,252],"Heart Failure With Preserved Ejection Fraction","Renal Denervation","2024-01-30",{"date":255,"type":44},"2024-02-01",{"date":257,"type":44},"2023-09-01",{"date":46,"type":21},{"name":50,"class":51},""]